SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB Biotherapeutics has presented positive safety and pharmacologic data from a GLP toxicology study for its first-in-class fully human immunotherapeutic, SAB-142, at FOCIS 2023. The treatment is being developed to delay onset and progression of Type 1 Diabetes (T1D) by targeting multiple immunological cell subsets associated with T1D and other autoimmune diseases. Results from the study showed ..